Oxford COVID vaccine Phase 2 trial begins at Pune hospital

Published On 2020-08-27 04:30 GMT | Update On 2021-08-19 08:03 GMT

New Delhi : The Phase II clinical trial of the Oxford Covid-19 vaccine, Covishield, began on Wednesday. The first dose was given to two males, aged 28 and 48, in Pune's Bharti Vidyapeeth's Medical College and Hospital.

"Two volunteers were given 0.5 ml of the vaccine, observed for half an hour to see if they get any local site reaction or systemic reaction. After half an hour, they were sent home and given an emergency helpline number. They will be observed for seven days," Medical Director of the medical college Dr Sanjay Lalwani told IANS.

"We received the vaccine yesterday and got clearance from the Serum Institute to start enrolling the volunteers. Five volunteers were called, and a RT-PCR test was performed to screen for antibodies. Three tested antibody positive with no history of Covid-19. They might have been asymptomatic carriers," he added.

Twenty five volunteers will be given the dosage in the coming days. A total of 100 volunteers will be enrolled throughout India.

"If the data of all the 100 shows fine, the government will give clearance for phase III on 1,500. It will see the immunogenicity to see how good antibodies are produced and safety of the vaccine. Once the data is compiled by DGCI, the vaccine will get clearance," said Lalwani.

The vaccine has been developed by Oxford University and British-Swedish pharmaceutical firm AstraZeneca.

The Serum Institute of India has tied up with AstraZeneca to produce doses of the vaccine in India. The trials will be conducted on 1,600 participants across the country.

Read also: Serum Institute Shuns Reports Of Commercializing Covishield, Says Will Sell Only After Successful Trial

Article Source : IANS

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

MD Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Oxford COVID vaccine Phase 2 trial begins at Pune hospital

Similar News

Shilpa Pharma Lifesciences Unit-1 successfully completes GMP inspection from Brazilian regulatory authority

Lupin rolls out Nasal spray for rhinorrhea relief in US

Pfizer Told To Conduct Phase IV Trial of Abrocitinib in Indian Adolescents with Atopic Dermatitis

CBI Cracks Down on PCI Chief Montu Patel in College Bribery Scandal

Submit Full Adverse Event Data from Lenvatinib Phase IV Liver Cancer Trial: CDSCO Panel To Eisai Pharma

Over 700 bottles of Codeine Cough Syrup seized, 2 arrested

Massive Rs 1.2 crore Oxytocin seizure in Lucknow, 3 held

High-Alcohol Medicinal Preparations to Come Under Schedule H1: Govt Panel Approves Rule Change